Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SHPH Shuttle Pharmaceuticals Inc

Market Closed 12-12 16:00:00 EST

1.79

+0.00

0.00%

盘后1.67

-0.12-6.70%

19:54 EST

High2.04	Low1.70	Vol591.22K
Open1.82	D1 Closing1.79	Amplitude18.99%
Mkt Cap2.87M	Tradable Cap2.72M	Total Shares1.60M
T/O1.10M	T/O Rate38.91%	Tradable Shares1.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SHPH","market":"US","secType":"STK","nameCN":"Shuttle Pharmaceuticals Inc","latestPrice":1.79,"timestamp":1765573200000,"preClose":1.79,"halted":0,"volume":591220,"hourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.79,"latestTime":"19:54 EST","volume":6911,"amount":12024.1381,"timestamp":1765587261720},"delay":0,"floatShares":1519600,"shares":1603300,"eps":-27.493763,"marketStatus":"Market Closed","change":0,"latestTime":"12-12 16:00:00 EST","open":1.82,"high":2.04,"low":1.7,"amount":1099692.5531900001,"amplitude":0.189944,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-27.493763,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1661918400000,"exchange":"NASDAQ","adjPreClose":1.79,"preHourTrading":{"tag":"盘前","latestPrice":1.79,"preClose":1.79,"latestTime":"09:28 EST","volume":17181,"amount":29894.0895405,"timestamp":1765549692538},"postHourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.79,"latestTime":"19:54 EST","volume":6911,"amount":12024.1381,"timestamp":1765587261720},"volumeRatio":2.2551159550420268},"requestUrl":"/m/hq/s/SHPH/wiki","defaultTab":"wiki","newsList":[{"id":"2587585927","title":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns As CFO Of Shuttle Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587585927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587585927?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:34","pubTimestamp":1764369272,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns As CFO Of Shuttle Pharmaceuticals - SEC FilingNov 28  - Shuttle Pharmaceuticals Holdings Inc SHPH.O:SHUTTLE PHARMACEUTICALS HOLDINGS INC - TIMOTHY LORBER RESIGNS AS CFO OF SHUTTLE PHARMACEUTICALS - SEC FILINGSHUTTLE PHARMACEUTICALS HOLDINGS INC - CHRISTOPHER COOPER ASSUMES ROLE OF CFO EFFECTIVE NOVEMBER 21, 2025 - SEC FILINGSHUTTLE PHARMACEUTICALS HOLDINGS INC - COOPER WILL SERVE IN THIS CAPACITY WHILE COM CONDUCTS SEARCH FOR PERMANENT CFOFurther company coverage: SHPH.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2587875830","title":"Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns as CFO of Shuttle Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587875830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587875830?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369115,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2587758307","title":"Shuttle Pharmaceuticals Holdings Inc - Cooper Will Serve in This Capacity While Com Conducts Search for Permanent CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2587758307","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587758307?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369115,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2587475830","title":"Shuttle Pharmaceuticals Names Christopher Cooper as Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2587475830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587475830?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369099,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. announced that Timothy Lorber has resigned as Chief Financial Officer, effective immediately. Christopher Cooper, who is currently serving as Interim Chief Executive Officer, has assumed the additional role of Chief Financial Officer while the company searches for a permanent replacement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL86ZNGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2586261198","title":"Shuttle Pharmaceuticals Announces Unregistered Sale of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261198","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261198?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:29","pubTimestamp":1764178151,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced the unregistered sale of shares in connection with its recent asset acquisition. Under the terms of an Asset Purchase Agreement completed on November 20, 2025, the company may issue shares of its common stock as part of the consideration for the transaction. These shares will be offered pursuant to exemptions provided under Section 4 of the Securities Act, Rule 506, and Regulation S, and will not be registered under the Securities Act. The total number of shares issued will not exceed 19.99% of the company's outstanding common stock as of the closing date without shareholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2qXY1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2585112452","title":"Stocks to Watch: Shuttle Pharma, Butterfly Network, Captivision","url":"https://stock-news.laohu8.com/highlight/detail?id=2585112452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585112452?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:38","pubTimestamp":1763768280,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals is discontinuing its cancer-drug trials after its partnership with Theradex ended. Shares fell 23% to $1.24 in after-hours trading Friday.Butterfly Network's director Lawrence Robbins bought 2.8 million shares. The stock gained 16% to $3.07 post market.Captivision said its chief executive would take on the responsibility of interim chief financial officer. The stock declined 4% to 75 cents after the market closed.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFLY","SHPH","BK4086","BK4082","CAPT","BK4139"],"gpt_icon":0},{"id":"2585125273","title":"Shuttle Pharmaceuticals Halts Ropidoxuridine Clinical Trials Amid Reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2585125273","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585125273?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:06","pubTimestamp":1763759199,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced a corporate reorganization following the termination of its master agreement with Theradex Systems, Inc. As part of this process, the company will discontinue its clinical trials of Ropidoxuridine, immediately ending enrollment and beginning winddown activities in compliance with FDA requirements. Shuttle Pharmaceuticals has reached a settlement with Theradex, agreeing to pay $300,000 in final settlement of outstanding liabilities totaling approximately $557,000. The company also disclosed it will remain liable for about $750,000 under separate research site agreements with various hospitals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLbhKrdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2585496071","title":"Shuttle Pharmaceuticals Closes Acquisition of Molecule.ai for $8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2585496071","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585496071?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:31","pubTimestamp":1763735460,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has completed the acquisition of the assets and liabilities of Molecule.ai, a Canadian artificial intelligence company focused on molecular discovery and drug development technologies. The agreement provides for a total purchase price of $8 million, paid in a mix of cash and Shuttle common stock, with an additional contingent payment of $2 million based on certain performance milestones. An initial payment of $3 million was made at closing. Molecule.ai's AI platform is expected to enhance Shuttle's capabilities in molecular modeling and predictive analytics, supporting the advancement of precision radiotherapy solutions and drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Ph","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL79ngCm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2585113776","title":"Lendway Shares Jump Nearly 20% After Hours — Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113776","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585113776?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:57","pubTimestamp":1763715420,"startTime":"0","endTime":"0","summary":"Lendway Inc. shares jumped nearly 20% in after-hours trading Thursday following a stock amendment filing and shareholder approval of an authorized share increase.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/21/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/21/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48997002/lendway-shares-jump-nearly-20-after-hours-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48997002/lendway-shares-jump-nearly-20-after-hours-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4009","LDWY","CFO","SHPH"],"gpt_icon":0},{"id":"2585118512","title":"Why Shuttle Pharmaceuticals (SHPH) Stock Surged Overnight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585118512","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585118512?lang=en_us&edition=fundamental","pubTime":"2025-11-21 15:52","pubTimestamp":1763711520,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals shares jumped 27.9% in after-hours trading Thursday after the company filed an S-1 registration statement and completed a $2.5 million private placement.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/21/shutterstock-2374266345.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/21/shutterstock-2374266345.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48996580/why-shuttle-pharmaceuticals-shph-stock-surged-overnight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48996580/why-shuttle-pharmaceuticals-shph-stock-surged-overnight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2584717056","title":"Shuttle Pharmaceuticals Faces Nasdaq Delisting Risk Over Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2584717056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584717056?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:06","pubTimestamp":1763413581,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced that it was not in compliance with Nasdaq Listing Rule 5550, which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity. The company reported stockholders' equity of $1,394,161 as of September 30, 2025. However, Shuttle Pharmaceuticals believes it has regained compliance following a private placement on November 4, 2025, which raised approximately $2.5 million in gross proceeds. Nasdaq will continue to monitor the company's compliance, and if it is not maintained by the next periodic report, Shuttle Pharmaceuticals may face delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7MsZBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2583548588","title":"Shuttle Pharmaceuticals Q3 EPS $(1.05) Up From $(39.75) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548588","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583548588?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:35","pubTimestamp":1763073356,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(1.05) per share. This is a 97.36 percent increase over losses of $(39.75) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853181/shuttle-pharmaceuticals-q3-eps-1-05-up-from-39-75-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","SQQQ","USJW.SI","NQmain",".IXIC","PSQ","QID","TQQQ","TSYW.SI","USAW.SI","BK4139","SHPH","MNQmain","QLD"],"gpt_icon":0},{"id":"2581839001","title":"Shuttle Pharmaceuticals Raises $2.5 Million in Private Placement of Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839001","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839001?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:07","pubTimestamp":1762549657,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced the completion of a private placement, raising approximately $2.5 million through the sale of a pre-funded warrant to purchase up to 625,156 shares of its common stock. The transaction, which closed on November 4, 2025, was conducted with a single investor in reliance on exemptions from registration under the Securities Act of 1933. WestPark Capital, Inc. acted as the exclusive placement agent and received a cash fee amounting to 4% of the gross proceeds. Shuttle Pharmaceuticals has agreed to file a registration statement with the SEC to register the resale of the shares issuable upon exercise of the warrant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL6Wsjsh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2580215745","title":"Shuttle Pharmaceuticals Raises $2.5 Million in Private Placement at $4.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215745","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215745?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:34","pubTimestamp":1762176885,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced it has entered into a securities purchase agreement with a single investor for a private placement, raising approximately $2.5 million in gross proceeds. The offering, which is expected to close on or about November 4, 2025, involves the issuance of a pre-funded warrant to purchase up to 625,156 shares of common stock at an effective price of $4.00 per share, which is above the market price under Nasdaq rules. The securities have not been registered under the Securities Act of 1933 and were offered only to accredited investors. Shuttle Pharma plans to use the net proceeds for marketing, general corporate purposes, and working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5CzK2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2579184623","title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for Director Angel Liriano","url":"https://stock-news.laohu8.com/highlight/detail?id=2579184623","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579184623?lang=en_us&edition=fundamental","pubTime":"2025-10-30 02:06","pubTimestamp":1761761178,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Angel Liriano as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDLsnj6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2579990619","title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for Director Sachin Pathigoda Arachchige","url":"https://stock-news.laohu8.com/highlight/detail?id=2579990619","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579990619?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:06","pubTimestamp":1761681998,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Pathigoda Arachchige Sachin Eranga as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL1nHCyD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2577807167","title":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Enters Binding Term Sheet With Molecule - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577807167","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577807167?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:59","pubTimestamp":1761080367,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Enters Binding Term Sheet With Molecule - SEC FilingOct 21  - Shuttle Pharmaceuticals Holdings Inc SHPH.O:SHUTTLE PHARMACEUTICALS HOLDINGS INC - ENTERS BINDING TERM SHEET WITH MOLECULE - SEC FILINGSHUTTLE PHARMACEUTICALS HOLDINGS INC - PURCHASE PRICE OF $10 MILLION PAYABLE IN CASH AND SHARES - SEC FILINGSource text: [ID:n0001493152-25-018788]Further company coverage: SHPH.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W2242:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2577980434","title":"Shuttle Pharmaceuticals to Acquire Molecule Assets for $10 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2577980434","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577980434?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:06","pubTimestamp":1761077209,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has entered into a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd.  for $10 million, payable in a mix of cash and company stock. Completion of the deal is subject to definitive agreements, board approval, and due diligence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL8Dn34x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2574109836","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2574109836","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574109836?lang=en_us&edition=fundamental","pubTime":"2025-10-11 01:39","pubTimestamp":1760117990,"startTime":"0","endTime":"0","summary":"USANA Health Sciences  shares slumped 22% after the company reported late Thursday preliminary Q3 results, saying it swung to an adjusted loss from a profit a year earlier.More than 379,000 shares traded intraday, compared with a daily average of about 129,000.Tian Ruixiang  said Friday it has struck a deal to sell shares and warrants to some institutional investors to raise about $3 million for the insurance broker operating in China.Shares sank 43% following an increase in intraday trading volume to over 634,000 from a daily average of about 129,000.Shuttle Pharmaceuticals  said it has signed a letter of intent to acquire Molecule.ai for $10 million in cash and shares, contingent on the completion of certain milestones.Shares of Shuttle dropped 24% as intraday trading volume grew to over 1.71 million from a daily average of roughly 125,000.Price: 20.26, Change: -5.98, Percent Change: -22.79","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SHPH","USNA","BK4183","BK4173","BK4532","TIRX"],"gpt_icon":0},{"id":"2574177695","title":"Shuttle Pharmaceuticals announces extension of LOI with Molecule.ai","url":"https://stock-news.laohu8.com/highlight/detail?id=2574177695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574177695?lang=en_us&edition=fundamental","pubTime":"2025-10-10 22:25","pubTimestamp":1760106315,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (SHPH) Holdings announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, an artificial inte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-announces-extension-of-loi-with-molecule-ai-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-announces-extension-of-loi-with-molecule-ai-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SHPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shuttlepharma.com","stockEarnings":[{"period":"1week","weight":0.0229},{"period":"1month","weight":-0.2869},{"period":"3month","weight":-0.5014},{"period":"6month","weight":-0.4608},{"period":"1year","weight":-0.8977},{"period":"ytd","weight":-0.9166}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.105539},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.059224},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.205518},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.023095},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.122933},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.116715},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.082532},{"month":8,"riseRate":0,"avgChangeRate":-0.223531},{"month":9,"riseRate":0.25,"avgChangeRate":-0.322851},{"month":10,"riseRate":0.25,"avgChangeRate":-0.104427},{"month":11,"riseRate":0.25,"avgChangeRate":-0.361431},{"month":12,"riseRate":0.75,"avgChangeRate":0.131657}],"exchange":"NASDAQ","name":"Shuttle Pharmaceuticals Inc","nameEN":"Shuttle Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shuttle Pharmaceuticals Inc,SHPH,Shuttle Pharmaceuticals Inc股票,Shuttle Pharmaceuticals Inc股票老虎,Shuttle Pharmaceuticals Inc股票老虎国际,Shuttle Pharmaceuticals Inc行情,Shuttle Pharmaceuticals Inc股票行情,Shuttle Pharmaceuticals Inc股价,Shuttle Pharmaceuticals Inc股市,Shuttle Pharmaceuticals Inc股票价格,Shuttle Pharmaceuticals Inc股票交易,Shuttle Pharmaceuticals Inc股票购买,Shuttle Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction